Heparin: Clinical Indications and Strategies for Bleeding Risk Prevention
DOI:
https://doi.org/10.11594/jk-risk.05.1.1Keywords:
heparinDownloads
References
Qiu M, Huang S, Luo C, et al. Pharmacological and clinical application of heparin progress: an essential drug for modern medicine. Biomed Pharmacother. 2021;139:111561. DOI: https://doi.org/10.1016/j.biopha.2021.111561
Paschoa AF. Heparin: 100 years of pleiotropic effects. J Thromb Thrombolysis. 2016;41(4):636–43. DOI: https://doi.org/10.1007/s11239-015-1261-z
Alyahya R, Sudha T, Racz M, Stain SC, Mousa SA. Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. Int J Oncol. 2015;46(3):1225–31. DOI: https://doi.org/10.3892/ijo.2014.2803
Mulloy B, Hogwood J, Gray E, Lever R, Page CP. Pharmacology of heparin and related drugs. Pharmacol Rev. 2016;68(1):76–141. DOI: https://doi.org/10.1124/pr.115.011247
Lui PL, Tan SC, Goh PW, et al. Improving the safety of heparin usage by standardisation of practice. BMJ Open Qual. 2025;14(2):e002952. doi:10.1136/bmjoq-2024-002952. DOI: https://doi.org/10.1136/bmjoq-2024-002952
Robson JP Jr. A review of hemodialysis vascular access devices: improving client outcomes through evidence-based practice. J Infus Nurs. 2013;36:404–10. DOI: https://doi.org/10.1097/NAN.0000000000000012
Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994–3018. DOI: https://doi.org/10.1161/01.CIR.103.24.2994
Stevens SM, Woller SC, Kreuziger LB, et al. An-tithrombotic therapy for VTE disease: second update of the CHEST guideline and expert pan-el report. Chest. 2021;160:e545–608. DOI: https://doi.org/10.1016/j.chest.2021.07.055
Bates DW, Cullen DJ, Laird N. Incidence of ad-verse drug events and potential adverse drug events. JAMA. 1995;274:29–34. doi:10.1001/jama.1995.03530010043033. DOI: https://doi.org/10.1001/jama.1995.03530010043033
Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a pro-spective analysis of 3695 patient-episodes. PLoS One. 2009;4:e4439. DOI: https://doi.org/10.1371/journal.pone.0004439
Piazza G, Nguyen TN, Cios D, et al. Anticoagula-tion-associated adverse drug events. Am J Med. 2011;124:1136–42. DOI: https://doi.org/10.1016/j.amjmed.2011.06.009
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jurnal Klinik dan Riset Kesehatan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges and earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
